Thousands of seniors will keep their slim waistlines thanks to a new Medicare bridge program launching on July 1. The Trump administration has extended a short-term deal to cover weight-loss miracle drugs like Wegovy and Zepbound for older Americans. The program ensures that the most favored nation price tags negotiated with Eli Lilly and Novo Nordisk will apply to the 65-and-over crowd. It is a temporary reprieve for the country’s most stylish retirees.

The program comes after major health insurers like UnitedHealth and Humana balked at the long-term costs of the shots. Under the extension, Medicare enrollees will pay a $50 monthly copay to access the medication. Analysts say the move blunts the immediate fear that demand for the drugs would plummet due to high prices. It is a billionaire-style subscription for the masses, at least through the end of 2027.

While the bridge program is a win for the present, the long-term outlook remains as cloudy as a bad martini. Permanent integration into Medicare plans has been delayed, leaving the future of the American waistline in limbo. For now, the goal of a zero-percent body fat ratio remains an attainable luxury for the Florida golf course set.